Pazoo (PZOO) 10-Q 15 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	3 Months Ended
	Mar. 31, 2014
Document and Entity Information	'
Entity Registrant Name	'Pazoo, Inc.
Document Type	'10-Q
Document Period End Date	31-Mar-14
Amendment Flag	'false
Entity Central Index Key	'0001533427
Current Fiscal Year End Date	'--12-31
Entity Common Stock, Shares Outstanding	107,765,750
Entity Public Float	$1,077,657
Entity Filer Category	'Smaller Reporting Company
Entity Current Reporting Status	'Yes
Entity Voluntary Filers	'No
Entity Well-known Seasoned Issuer	'No
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q1

BALANCE_SHEETS_Unaudited

BALANCE SHEETS (Unaudited) (USD $)	Mar. 31, 2014		Dec. 31, 2013
Current assets:	'		'
Cash and cash equivalents	$28,499		$35,848
Accounts receivable	40,998		33,461
Inventories	2,564		4,129
Deposit	50,000		0
Prepaid expenses	24,058		1,911
Total current assets	146,119		75,349
Total assets	146,119		75,349
Current liabilities:	'		'
Accounts payable and accrued liabilities	74,847		64,846
Interest payable	6,000		0
Loans payable	3,000		3,000
Convertible debt	21,728	[1]	1,849	[1]
Derivative liability	603,236		172,049
Total current liabilities	708,811		241,744
Total liabilities	708,811		241,744
Stockholders' deficit	'		'
Common stock	107,766		101,410
Convertible preferred stock, Ser. A	1,086		923
Preferred stock, Ser. B	1,187		1,187
Additional paid-in capital	2,494,923		2,250,451
Retained deficit	-3,167,654		-2,520,366
Total stockholders' deficit	-562,692		-166,395
Total liabilities and stockholders' equity (deficit)	$146,119		$75,349
[1]	Net of discount of $95,333.

Statement_of_Financial_Positio

Statement of Financial Position - Parenthetical (USD $)	Mar. 31, 2014	Dec. 31, 2013
Preferred Stock, Par Value	$0	$0
Preferred Stock, Shares Authorized	0	0
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$0.00	$0.00
Common Stock, Shares Authorized	980,000,000	980,000,000
Common Stock, Shares Issued	107,765,750	101,409,500
Common Stock, Shares Outstanding	107,765,750	101,409,500
Warrants Issued	7,000,000	2,400,000
Warrants Outstanding	7,000,000	2,400,000
Preferred Stock Series A	'	'
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	1,086,394	1,086,394
Preferred Stock, Shares Outstanding	923,394	923,394
Preferred Stock Series B	'	'
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Authorized	2,500,000	2,500,000
Preferred Stock, Shares Issued	1,187,500	1,375,000
Preferred Stock, Shares Outstanding	1,187,500	1,375,000
Preferred Stock Series C	'	'
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Authorized	7,500,000	7,500,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

STATEMENT_OF_OPERATIONS_Unaudi

STATEMENT OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Net sales	'	'
Service Revenue - sales	$0	$0
Merchandise Sales - sales	218	4,370
Advertising Sales - sales	17,109	0
Total Income	17,327	4,370
Cost of goods sold	'	'
Service Revenue - cost	0	0
Merchandise Sales - cost	325	4,603
Total Cost of Goods Sold	325	4,603
Gross profit (loss)	17,002	-233
Selling, general and administrative expenses	206,458	93,705
Bad debt Expense	0	0
Professional fees	35,433	40,747
Website setup	22,408	19,645
Total operating expenses	264,299	154,097
Loss from operations	-247,297	-154,330
Gain/loss on derivative liability	-376,187	0
Amortization of debt discount	-17,804	0
Interest expense	-6,000	-15
Net loss	-647,288	-154,345
Series A preferred stock dividend	-5,672	-21,687
Net loss attributable to common stockholders	($652,960)	($176,032)
Weighted average common shares outstanding - Basic and diluted	105,994,083	75,325,972
Net loss per common share - Basic and diluted	($0.01)	$0

STATEMENT_OF_CASH_FLOWS_Unudit

STATEMENT OF CASH FLOWS (Unudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net loss	($647,288)	($154,345)
Common stock issued for services	110,991	39,048
Loss on derivative liability	376,187	0
Amortization of debt discount	17,804	0
Accounts receivable (increase/decrease)	-7,537	987
Inventories (increase/decrease)	1,565	-678
Prepaid expenses and other current assets	-22,147	-881
Interest payable (increase/decrease)	6,000	0
Accounts payable and accrued liabilities (increase/decrease)	12,076	17,865
Net cash used in operating activities	-152,349	-98,004
Cash flows from investing activities:	'	'
Deposit made on acquisition of investment	-50,000	0
Net cash used in investing activities	-50,000	0
Cash flows from financing activities:	'	'
Borrowings on convertible note	55,000	0
Proceeds from exercise of Series A preferred warrants	40,000	0
Proceeds from sale of Series A preferred stock	100,000	0
Net cash provided by financing activities	195,000	0
Net increase in cash and cash equivalents	-7,349	-98,004
Cash and cash equivalents beginning of period	35,848	130,556
Cash and cash equivalents end of period	28,499	32,552
Supplemental Disclosure of Cash Flows Information	'	'
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Noncash Investing and Financing Activities	'	'
Common stock issued for the conversion of SeriesA preferred stock	1,700	4,250
Debt discount	60,500	0
Payments of AP by third party	2,075	0
Original issue discount on convertible note	$5,500	$0

Note_1Description_of_Business_

Note 1-Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Notes	'
Note 1-Description of Business and Basis of Presentation	'
	Note 1—DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
	Basis of Presentation
	The accompanying unaudited interim financial statements of Pazoo, Inc. (“we”, “our”, “Pazoo” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with Pazoo’s audited 2013 annual financial statements and notes thereto filed on Form 10-K with the SEC. In the opinion of management, all adjustments, consisting of normal reoccurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods present have been reflected herein. The results of operation for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements, which would substantially duplicate the disclosure required in Pazoo’s fiscal 2013 financial statements have been omitted.
	Description of Business
	We are an early growth stage health and wellness company. Presently, our primary business is pazoo.com, an online, content driven, ad supported health and wellness web site for people and their pets. Additionally, this site has e-commerce functionality which allows pazoo.com to be an online retailer of nutritional foods/supplements, wellness goods, and fitness apparel. Pazoo, Inc. does not have any brick and mortar establishments.

Note_2Going_Concern

Note 2-Going Concern	3 Months Ended
	Mar. 31, 2014
Notes	'
Note 2-Going Concern	'
	Note 2—GOING CONCERN
	From inception of November 16, 2010 through March 31, 2014, the Company has incurred net losses of $3,167,654.    This factor, among others, raises significant doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.  The Company’s continuation as a going concern is dependent upon our ability to generate sufficient cash flow to meet our obligations on a timely basis and ultimately attain profitability.  Management believes that we can alleviate the facts and circumstances which indicate a going concern by expanding our services, expert advice and online products. We aim to become more than a web based company by providing information, services and products through direct response, retail, and advertising revenue, in addition to our website.

Note_3Stockholders_Equity

Note 3-Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Notes	'
Note 3-Stockholders' Equity	'
	Note 3—STOCKHOLDERS’ EQUITY
	Common Stock
	In January 2014, the Company issued 3,000,000 common shares valued at $63,000 in exchange for consulting services provided.  Provided that the consultant performs all tasks within the scope of work, an additional 3,000,000 shares will be due to be issued on or about January 1, 2015 with those shares vesting 1,500,000 shares on July 1, 2015 and the remaining 1,500,000 shares on December 31, 2015.  All shares issued are subject to a contractual lock-up provision.
	In January 2014, the Company issued 556,250 shares to various consultants for services valued at $11,851.
	In March 2014, ICPI converted 170,000 shares of Series A Convertible Preferred Stock into 1,700,000 common shares.
	In March 2014 the Company issued an aggregate amount of 1,100,000 common shares. This included shares issued to individuals who are affiliated with the “Pazoo Experts” section of our Company website.  In exchange for services rendered, or to be rendered, as expert contributors on our Company website. These shares and the value of the pro-rata shares to be issued of 1,175,000 was $36,140 as of March 31, 2014.
	Preferred Stock
	In January 2014, the Company issued 800,000 shares of Series A Preferred Stock to ICPI in exchange for $40,000 in accordance with the exercise of warrants.
	In March 2014, the Company effectuated a 10 for 1 reverse stock split on the Company’s Series A Convertible Preferred Stock (See Exhibit 99.2 3-17-14 Board Resolution), and the Company amended all of the previous Investment Agreements with ICPI collectively.
	In March 2014, the Company entered into a new Investment Agreement (Investment Agreement No. 4) with Integrated Capital Partners, Inc. (“ICPI”).  The Investment Agreement provides that in exchange for an investment of up to $500,000 ICPI could acquire up to 500,000 shares of Series A Preferred Stock at the rate of $1.00 per share.
	In March 2014, the Company issued 100,000 shares of Series A Preferred Stock to ICPI in exchange for $100,000, in accordance with Investment Agreement No. 4
	On March 31, 2014, we recorded a Series A Preferred dividend in the amount of 11,969 shares.
	Warrants
	Simultaneous with the issuance of Series A Preferred Stock in the three month period ending March 31, 2014, and under the Investment Agreement No. 4 (March 2014) we issued 100,000 warrants to ICPI which entitles its owner to purchase one share of Series A Preferred Stock for each Series A Preferred Stock at an exercise price of $2.00, subject to the terms of the warrant agreement between the warrant agent and us.  The warrants are exercisable five years from the date of issuance.
	The following table presents the Series A preferred stock warrant activity during the three months ended March 31, 2014:
		Warrants		Weighted Average Exercise Price
	Outstanding - December 31, 2013		823,226	$	2.2
	Granted		100,000		-
	Forfeited/Canceled		-		-
	Exercised		80,000		-
	Outstanding - March 31, 2014		843,226		2.34
	Exercisable- March 31, 2014		843,226	$	2.34
	The weighted average remaining life of the outstanding Series A preferred stock warrants as of March 31, 2014 and December 31, 2013 was 3.78 and 3.92 years, respectively.
	The following table presents the common stock warrant activity during the three months ended March 31, 2014:
		Warrants		Weighted Average Exercise Price
	Outstanding - December 31, 2013		5,000,000	$	0.05
	Granted		-		-
	Forfeited/Canceled		-		-
	Exercised		-		-
	Outstanding - March 31, 2014		5,000,000		0.05
	Exercisable- March 31, 2014		5,000,000	$	0.05
	The weighted average remaining life of the outstanding common stock warrants as of March 31, 2014 and December 31, 2013 was 1.02 and 1.26 years, respectively.

Note_4Loans_Payable

Note 4-Loans Payable	3 Months Ended
	Mar. 31, 2014
Notes	'
Note 4-Loans Payable	'
	Note 4—LOANS PAYABLE
	In February 2014, the Company entered into a convertible Promissory note totaling $16,601 with ICPI for office space through February 2015.  ICPI may convert all or any part of the outstanding and unpaid principal into shares of Series A Preferred Stock at a price of $0.50 per share.

Note_5Equity_Interest

Note 5-Equity Interest	3 Months Ended
	Mar. 31, 2014
Notes	'
Note 5-Equity Interest	'
	Note 5—EQUITY INTEREST
	In April 2014, the Company agreed to buy a 40% equity interest in MA and Associates, LLC for $2,000,000 and 150,000 shares of the Company’s Series C Preferred Stock.   MA is in the process of becoming a licensed medical marijuana testing laboratory in the State of Nevada.  The Company made a $50,000 down payment which was recorded as a deposit in March 2014 subsequently made a $50,000 investment in April 2014.  As of March 31, 2014, the Company does not own any interest in MA.

Note_6Convertible_Note_and_Der

Note 6-Convertible Note and Derivative Liabilities	3 Months Ended
	Mar. 31, 2014
Notes	'
Note 6-Convertible Note and Derivative Liabilities	'
	Note 6—CONVERTIBLE NOTE AND DERIVATIVE LIABILITIES
	On December 4, 2013 the Company entered into a $500,000 Promissory Note with JMJ Financial. (Attached as Exhibit 99.02 to the Company's Form 8-K filed December 17, 2013).  Under the terms, the Company will receive one or more installments on a periodic basis and will have 90 days for the date of each installment in which to repay the principal amount of the loan and interest. In the event repayment is not made within the 90 day period, JMJ shall have the right to convert any unpaid sums into common stock of the Company at the rate of the lesser of $.05 per share or 60% of the lowest trade reported in the 25 days prior to conversion. As of December 31, 2013, the Company received $50,000 of the note.
	During 2013, the Company recorded a discount of $50,000 on the note of which $1,849 was amortized as of year-end.  During the quarter ended March 31, 2014, $12,500 was recorded to amortization expense.
	On or about February 27, 2014 the Company entered into a $220,000 10% Convertible Promissory Note with Iconic Holdings, LLC (“Iconic”).  As of March 31, 2014, the Company received $60,500. Under the terms of the Promissory Note (the “Note”) the Company will receive principal in one or more installments with a Maturity Date for the Note of February 27, 2015.  Iconic shall have the right to convert any unpaid sums into common stock of the Company at the rate of the lesser of $.01 per share or 50% of the lowest trade reported in the 25 days prior to date of conversion.  (Attached as Exhibit 99.03 to the Company's Form 8-K filed March 27, 2014)
	During the first quarter of  2014, the Company recorded a discount of $60,500 on the note of which $5,304 was amortized as of March 31, 2014. Of that amount, $5,500 was an original issuance discount on the note.
	The following table summarizes the changes in the derivative liabilities during the period ending March 31, 2014:
	Balance as of December 31, 2013	$	172,049
	Debt discount		60,500
	Original issuance discount		-5,500
	Change in fair value		376,187
	Ending balance as of December 31, 2013	$	603,236
	The Company uses the Black Scholes Option Pricing Model to value its option based derivatives based upon the following assumptions: dividend yield of -0-%, volatility of 167%, risk free rate of 0.33% and an expected term equal to the remaining term of the note.
	There were 5,000,000 common stock warrants outstanding on the date the convertible note agreement was entered into which became tainted. These warrants were valued using the Black Scholes Option Pricing Model based upon the following assumptions: dividend yield of -0-%, volatility of 203%, risk free rate of 0.44% and an expected term equal to the remaining exercise term of the warrants. The fair value of the warrants at March 31, 2014 was $142,110.

Note_7Fair_Value_Measurements_

Note 7-Fair Value Measurements and Derivative Liabiliity	3 Months Ended
	Mar. 31, 2014
Notes	'
Note 7-Fair Value Measurements and Derivative Liabiliity	'
	Note 7—FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILIITY
	The Company evaluates all of it financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.
	Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
	Under ASC-815 the conversion options embedded in the notes payable described in Note 5 require liability classification because they do not contain an explicit limit to the number of shares that could be issued upon settlement.
	During the period ending March 31, 2014, the Company entered into one convertible note agreement. The conversion option and the outstanding common stock warrants on that date which were tainted by the convertible note were classified as derivative liabilities at their fair value on the date of issuance.
	As defined in FASB ASC 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilized the market data of similar entities in its industry or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. FASB ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).
	The three levels of the fair value hierarchy are as follows:
	Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.
	Level 2 - Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date.
	Level 3 - Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.
	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value at the period ending March 31, 2014.
	Recurring Fair Value Measurements	Level 1		Level 2		Level 3		Total
	LIABILITIES:
	Derivative liability- March 31, 2014		-		-		603,236		603,236
	Derivative liability- 2013		-		-		172,049		172,049
	Derivative liability- 2012		-		-		-		-

Note_8Subsequent_Events

Note 8-Subsequent Events	3 Months Ended
	Mar. 31, 2014
Notes	'
Note 8-Subsequent Events	'
	Note 8—SUBSEQUENT EVENTS
	In accordance with FASB ASC 855-10-50-1 we evaluated our subsequent events through May 12, 2014.
	In April 2014 the Company issued 125,000 shares of Series A Preferred Stock to ICPI in exchange for $125,000.
	Simultaneous with the issuance of Series A Preferred Stock in April 2014, and under the Investment Agreement No. 4 we issued 125,000 warrants to ICPI which entitles its owner to purchase one share of Series A Preferred Stock for each Series A Preferred Stock at an exercise price of $2.00, subject to the terms of the warrant agreement between the warrant agent and us.
	In April 2014, the Company entered into an Equity Purchase Agreement and a Securities Purchase Agreement with Premier Venture Partners, LLC (“Premier”) whereby Premier is obligated, providing the Company has met certain conditions including the filing of a Form S-1 Registration Statement for the shares to be acquired, to purchase up to $5,000,000 of the Company’s common stock at the rates set forth at the request of the Company by issuing a Put Notice when funds are needed.  The Securities Purchase Agreement is a facility whereby the Company will receive $22,500 pursuant to two Convertible Promissory Notes.
	In April 2014 the Company issued 150,000 shares of Series A Preferred Stock to ICPI in exchange for $150,000.  The Company also simultaneously issued 150,000 warrants to ICPI which entitles its owner to purchase one share of Series A Preferred Stock for each Series A Preferred Stock acquired at an exercise price of $2.00.
	In April 2014, the Company entered into a $10,000 Convertible Promissory Note (the “Note”) with Premier Venture Partners, LLC.  Under the terms of the Note the Company’s will receive $10,000 for the preparation and filing of the Form S-1 Registration Statement required for the Equity Purchase Agreement (Attached as Exhibit 99.02 to the Company's Form 8-K filed April 9, 2014). Premier Venture Partners, LLC shall have the right to convert any unpaid sums into common stock of the Company at the rate of the lesser of $.03 per share or 50% of the lowest trade reported in the 10 days prior to date of conversion.  A second Convertible Promissory Note, in the amount of $12,500, will be issued after the Form S-1 Registration Statement is filed in order to cover any additional expense of making the Form S-1 Registration Statement effective.
	In April 2014, the Company agreed to buy a 40% equity interest in MA and Associates, LLC for $2,000,000 and 150,000 shares of the Company’s Series C Preferred Stock. MA is in the process of becoming a licensed medical marijuana testing laboratory in the State of Nevada. The Company made a $50,000 down payment in March 2014.
	In May 2014, the Company entered into a 12% Convertible Note (the “Note”) with JSJ Investments, Inc. (“JSJ”) in the amount of $100,000.  Prior to October 28, 2014, the Company may redeem the Note for a $150,000.  Thereafter, JSJ may convert the Note into common stock of the company at a stated discount of 50% based on the average of the lowest three trades in the previous ten days, or $0.06 per share.
	In May 2014 the Company issued 25,000 shares of Series A Preferred Stock to ICPI in exchange for $25,000, in accordance with Investment Agreement No. 4
	Simultaneous with the issuance of Series A Preferred Stock in May 2014, and under the Investment Agreement No. 4 we issued 25,000 warrants to ICPI which entitles its owner to purchase one share of Series A Preferred Stock for each Series A Preferred Stock at an exercise price of $2.00, subject to the terms of the warrant agreement between the warrant agent and us.

Note_1Description_of_Business_1

Note 1-Description of Business and Basis of Presentation: Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2014
Policies	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited interim financial statements of Pazoo, Inc. (“we”, “our”, “Pazoo” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with Pazoo’s audited 2013 annual financial statements and notes thereto filed on Form 10-K with the SEC. In the opinion of management, all adjustments, consisting of normal reoccurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods present have been reflected herein. The results of operation for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements, which would substantially duplicate the disclosure required in Pazoo’s fiscal 2013 financial statements have been omitted.

Note_1Description_of_Business_2

Note 1-Description of Business and Basis of Presentation: Description of Business (Policies)	3 Months Ended
	Mar. 31, 2014
Policies	'
Description of Business	'
	Description of Business
	We are an early growth stage health and wellness company. Presently, our primary business is pazoo.com, an online, content driven, ad supported health and wellness web site for people and their pets. Additionally, this site has e-commerce functionality which allows pazoo.com to be an online retailer of nutritional foods/supplements, wellness goods, and fitness apparel. Pazoo, Inc. does not have any brick and mortar establishments.

Note_3Stockholders_Equity_Comm

Note 3-Stockholders' Equity: Common Stock (Policies)	3 Months Ended
	Mar. 31, 2014
Policies	'
Common Stock	'
	Common Stock
	In January 2014, the Company issued 3,000,000 common shares valued at $63,000 in exchange for consulting services provided.  Provided that the consultant performs all tasks within the scope of work, an additional 3,000,000 shares will be due to be issued on or about January 1, 2015 with those shares vesting 1,500,000 shares on July 1, 2015 and the remaining 1,500,000 shares on December 31, 2015.  All shares issued are subject to a contractual lock-up provision.
	In January 2014, the Company issued 556,250 shares to various consultants for services valued at $11,851.
	In March 2014, ICPI converted 170,000 shares of Series A Convertible Preferred Stock into 1,700,000 common shares.
	In March 2014 the Company issued an aggregate amount of 1,100,000 common shares. This included shares issued to individuals who are affiliated with the “Pazoo Experts” section of our Company website.  In exchange for services rendered, or to be rendered, as expert contributors on our Company website. These shares and the value of the pro-rata shares to be issued of 1,175,000 was $36,140 as of March 31, 2014.

Note_3Stockholders_Equity_Pref

Note 3-Stockholders' Equity: Preferred Stock (Policies)	3 Months Ended
	Mar. 31, 2014
Policies	'
Preferred Stock	'
	Preferred Stock
	In January 2014, the Company issued 800,000 shares of Series A Preferred Stock to ICPI in exchange for $40,000 in accordance with the exercise of warrants.
	In March 2014, the Company effectuated a 10 for 1 reverse stock split on the Company’s Series A Convertible Preferred Stock (See Exhibit 99.2 3-17-14 Board Resolution), and the Company amended all of the previous Investment Agreements with ICPI collectively.
	In March 2014, the Company entered into a new Investment Agreement (Investment Agreement No. 4) with Integrated Capital Partners, Inc. (“ICPI”).  The Investment Agreement provides that in exchange for an investment of up to $500,000 ICPI could acquire up to 500,000 shares of Series A Preferred Stock at the rate of $1.00 per share.
	In March 2014, the Company issued 100,000 shares of Series A Preferred Stock to ICPI in exchange for $100,000, in accordance with Investment Agreement No. 4
	On March 31, 2014, we recorded a Series A Preferred dividend in the amount of 11,969 shares.

Note_3Stockholders_Equity_Warr

Note 3-Stockholders' Equity: Warrants (Policies)	3 Months Ended
	Mar. 31, 2014
Policies	'
Warrants	'
	Warrants
	Simultaneous with the issuance of Series A Preferred Stock in the three month period ending March 31, 2014, and under the Investment Agreement No. 4 (March 2014) we issued 100,000 warrants to ICPI which entitles its owner to purchase one share of Series A Preferred Stock for each Series A Preferred Stock at an exercise price of $2.00, subject to the terms of the warrant agreement between the warrant agent and us.  The warrants are exercisable five years from the date of issuance.
	The following table presents the Series A preferred stock warrant activity during the three months ended March 31, 2014:
		Warrants		Weighted Average Exercise Price
	Outstanding - December 31, 2013		823,226	$	2.2
	Granted		100,000		-
	Forfeited/Canceled		-		-
	Exercised		80,000		-
	Outstanding - March 31, 2014		843,226		2.34
	Exercisable- March 31, 2014		843,226	$	2.34
	The weighted average remaining life of the outstanding Series A preferred stock warrants as of March 31, 2014 and December 31, 2013 was 3.78 and 3.92 years, respectively.
	The following table presents the common stock warrant activity during the three months ended March 31, 2014:
		Warrants		Weighted Average Exercise Price
	Outstanding - December 31, 2013		5,000,000	$	0.05
	Granted		-		-
	Forfeited/Canceled		-		-
	Exercised		-		-
	Outstanding - March 31, 2014		5,000,000		0.05
	Exercisable- March 31, 2014		5,000,000	$	0.05
	The weighted average remaining life of the outstanding common stock warrants as of March 31, 2014 and December 31, 2013 was 1.02 and 1.26 years, respectively.

Note_3Stockholders_Equity_Warr1

Note 3-Stockholders' Equity: Warrants: Schedule of Preferred Units (Tables)	3 Months Ended
	Mar. 31, 2014
Tables/Schedules	'
Schedule of Preferred Units	'
		Warrants		Weighted Average Exercise Price
	Outstanding - December 31, 2013		823,226	$	2.2
	Granted		100,000		-
	Forfeited/Canceled		-		-
	Exercised		80,000		-
	Outstanding - March 31, 2014		843,226		2.34
	Exercisable- March 31, 2014		843,226	$	2.34

Note_3Stockholders_Equity_Warr2

Note 3-Stockholders' Equity: Warrants: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables)	3 Months Ended
	Mar. 31, 2014
Tables/Schedules	'
Schedule of Stockholders' Equity Note, Warrants or Rights	'
		Warrants		Weighted Average Exercise Price
	Outstanding - December 31, 2013		5,000,000	$	0.05
	Granted		-		-
	Forfeited/Canceled		-		-
	Exercised		-		-
	Outstanding - March 31, 2014		5,000,000		0.05
	Exercisable- March 31, 2014		5,000,000	$	0.05

Note_6Convertible_Note_and_Der1

Note 6-Convertible Note and Derivative Liabilities: Schedule of Derivative Liabilities at Fair Value (Tables)	3 Months Ended
	Mar. 31, 2014
Tables/Schedules	'
Schedule of Derivative Liabilities at Fair Value	'
	Balance as of December 31, 2013	$	172,049
	Debt discount		60,500
	Original issuance discount		-5,500
	Change in fair value		376,187
	Ending balance as of December 31, 2013	$	603,236

Note_7Fair_Value_Measurements_1

Note 7-Fair Value Measurements and Derivative Liabiliity: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)	3 Months Ended
	Mar. 31, 2014
Tables/Schedules	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	'
	Recurring Fair Value Measurements	Level 1		Level 2		Level 3		Total
	LIABILITIES:
	Derivative liability- March 31, 2014		-		-		603,236		603,236
	Derivative liability- 2013		-		-		172,049		172,049
	Derivative liability- 2012		-		-		-		-

Note_2Going_Concern_Details

Note 2-Going Concern (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Details	'	'
Retained deficit	$3,167,654	$2,520,366

Note_3Stockholders_Equity_Pref1

Note 3-Stockholders' Equity: Preferred Stock (Details)	3 Months Ended
	Mar. 31, 2014
Details	'
Preferred Stock Dividends, Shares	11,969

Note_6Convertible_Note_and_Der2

Note 6-Convertible Note and Derivative Liabilities (Details) (USD $)	Mar. 31, 2014
Details	'
Warrants and Rights Outstanding	$142,110